Fengshuo Zhu1, Xiaoguang Li1, Xiao Tang1, Junjian Jiang1, Yu Han1, Yinuo Li2, Chunyue Ma1, Zhonglong Liu1, Yue He1. 1. Department of Oral Maxillofacial‑Head and Neck Oncology, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, National Clinical Research Center for Oral Disease, Shanghai Key Laboratory of Stomatology and Shanghai Research Institute of Stomatology, Shanghai 200011, P.R. China. 2. Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Abstract
Head and neck squamous cell carcinoma (HNSCC), one of the most common malignancies worldwide, often has a poor prognosis due to the associated metastasis and chemoresistance. Hence, the development of more effective chemotherapeutics is critical. Neferine, a bisbenzylisoquinoline alkaloid isolated from the seed embryo of Nelumbo nucifera (common name: Lotus), exerts antitumor effects by regulating apoptosis and autophagy pathways, making it a potential therapeutic option for HNSCC. In our study, it was revealed that neferine inhibited the growth and induced the apoptosis of HNSCC cells both in vitro and in vivo. Furthermore, the results revealed that neferine activated the ASK1/JNK pathway by increasing reactive oxygen species production, resulting in the subsequent induction of apoptosis and the regulation of canonical autophagy in HNSCC cells. Moreover, a novel pro‑apoptotic mechanism was described for neferine via the activation of caspase‑8 following the accumulation of p62, which was caused by autophagic flux inhibition. These findings provided insights into the mechanisms responsible for the anticancer effect of neferine, specifically highlighting the crosstalk that occured between apoptosis and autophagy, which was mediated by p62 in HNSCC. Hence, the neferine‑induced inhibition of autophagic flux may serve as the basis for a potential adjuvant therapy for HNSCC.
Head and neck squamous cell carcinoma (HNSCC), one of the most common malignancies worldwide, often has a poor prognosis due to the associated metastasis and chemoresistance. Hence, the development of more effective chemotherapeutics is critical. Neferine, a bisbenzylisoquinoline alkaloid isolated from the seed embryo of Nelumbo nucifera (common name: Lotus), exerts antitumor effects by regulating apoptosis and autophagy pathways, making it a potential therapeutic option for HNSCC. In our study, it was revealed that neferine inhibited the growth and induced the apoptosis of HNSCC cells both in vitro and in vivo. Furthermore, the results revealed that neferine activated the ASK1/JNK pathway by increasing reactive oxygen species production, resulting in the subsequent induction of apoptosis and the regulation of canonical autophagy in HNSCC cells. Moreover, a novel pro‑apoptotic mechanism was described for neferine via the activation of caspase‑8 following the accumulation of p62, which was caused by autophagic flux inhibition. These findings provided insights into the mechanisms responsible for the anticancer effect of neferine, specifically highlighting the crosstalk that occured between apoptosis and autophagy, which was mediated by p62 in HNSCC. Hence, the neferine‑induced inhibition of autophagic flux may serve as the basis for a potential adjuvant therapy for HNSCC.
Entities:
Keywords:
apoptosis; autophagy; head and neck squamous cell carcinoma; neferine
Head and neck squamous cell carcinoma (HNSCC) originates from the mucosal surfaces of the oral cavity, oropharynx, larynx, and hypopharynx, accounting for more than 90% of the cancers of the head and neck (1). As the sixth most common cancer worldwide, HNSCC is highly aggressive and characterized by complex genetic alterations, and current treatment options for HNSCC consist of surgical interventions, radiotherapy, and chemotherapy (2,3). Although a number of advances have been made in these modalities, the recurrence rate remains high owing to the development of chemotherapy resistance, resulting in a low overall patient survival rate (4,5). Therefore, the identification of novel chemotherapeutic agents is urgently needed to prevent cancer recurrence and delay cancer progression.Compounds derived from plants have significantly contributed to the development of novel anticancer therapeutics. Nelumbo nucifera (common name: Lotus) is widely used in Indian and Chinese medicine for cardiovascular (6) and pulmonary (7) diseases as well as nervous system-related disorders (8). In addition, neferine, the major bisbenzylisoquinoline alkaloid isolated from the seed embryo of the lotus, has recently been revealed to exert antitumor effects through various pathways. For instance, neferine reportedly inhibited the proliferation and growth of prostate cancer cell (9), osteosarcoma (10), hepatocellular carcinoma (11), and lung cancer cells (12). Neferine also exhibited the ability to suppress the migration of gastrointestinal stromal tumor cells (13) and glioma cells (14). Furthermore, recent research suggests that neferine induces autophagy (15) and inhibits ovarian cancer cell angiogenesis (16). However, the effects of neferine on HNSCC have not yet been elucidated.Macroautophagy is a major intracellular catabolic mechanism that directs the degradation of cytoplasmic components and organelles in the lysosome (17) that can have cytoprotective or cytopathic roles in response to various stresses, including therapeutic stress. Autophagic flux denotes the complete process of autophagy, including autophagosome biogenesis, maturation, fusion with lysosomes, and the breakdown of autophagic substrates inside the lysosome (18). Indeed, autophagic flux induction or inhibition using natural compounds has shown promise in the treatment of diseases such as cancer (19). Additionally, apoptosis, another critical catabolic pathway essential for the cellular response to toxic agents, participates in extensive crosstalk with autophagy (20), rendering both pathways crucial for the development of effective cancer therapeutics.Therefore, in the present study, HNSCC cell lines and a xenograft mouse model were used to investigate the antitumor mechanism of neferine between autophagy and apoptosis, with the aim of presenting a promising alternative therapeutic agent for HNSCC.
Materials and methods
Cell lines and culture
The HNSCC cell lines used in the present study were HN6 (tongue squamous cell carcinoma; provided by the Shanghai Ninth People's Hospital, Shanghai, China), HN30 (pharyngeal squamous cell carcinoma; provided by the University of Maryland School of Dentistry, Maryland, USA) and Cal27 (tongue squamous cell carcinoma; purchased from ATCC). The control cell line was the human immortalized oral epithelial cell line (HIOEC), which was established by the Shanghai Ninth People's Hospital (21). All cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin (Gibco; Thermo Fisher Scientific, Inc.). Cells were cultured in a humidified atmosphere containing 5% CO2 at 37°C.
Cell proliferation assay
Cell viability was determined using the Cell Counting Kit-8 (CCK-8) assay kit (Dojindo Molecular Technologies, inc.). Briefly, HN6, HN30 and CAL27 cells were seeded at a density of 5×103 cells/well in a 96-well plate, with 200 µl DMEM medium (10% FBS). After incubation with indicated concentrations of neferine (0, 7.5, 15, 22.5 and 30 µM; MCE), 10 µl CCK-8 reagent was added to each well, and the absorbance was measured at 450 nm after 2 h of incubation at 37°C in the incubator. All experiments were repeated in triplicate.
Clonogenic assay
For the clonogenic assay, HN6, HN30 and CAL27 single-cell suspensions were prepared. A total of 500 cells were seeded/well in 6-well plates at 37°C overnight. The cells were treated with various concentrations (0, 1, 2, 5 and 10 µM) of neferine for 2 weeks. Cell colonies were fixed with pure methanol for 15 min and stained with 0.1% crystal violet (Beyotime Biotechnology) for 30 min at room temperature. The images were captured and scored with CanoScan 5600F (Canon, Inc.). Colonies of >50 cells were counted to determine the surviving fraction. All experiments were repeated in triplicate.
Cell cycle analysis
Single-cell suspensions were prepared, and 3×105 cells were seeded per well in 6-well plates overnight in the cell incubator. After treatment with various concentrations of neferine (0, 5, 10, 15 and 20 µM) for 24 h, HN6, HN30 and CAL27 cells were collected and fixed in 3 ml cold 75% ethanol at -20°C overnight. After washing with 2 ml of cold PBS, the cells were resuspended and incubated with 0.5 ml of PBS containing 100 µg/ml RNase (Beyotime Biotechnology) and 5 µg/ml propidium iodide (Shanghai Yeasen Biotechnology Co., Ltd.) at room temperature for 30 min. The cell cycle distribution was analyzed via BD FACSCalibur flow cytometer (BD Biosciences) and ModFIT 5.0 software (Verity Software House, Inc.).
Annexin V apoptosis assay
Apoptotic cells were identified using the FITC Annexin V Apoptosis Detection Kit (BD Biosciences). A total of 3×105 cells were seeded per well in 6-well plates overnight in the cell incubator. After treatment with the indicated concentrations (0, 5, 10, 15 and 20 µM) of neferine for 48 h, the cells were resuspended in binding buffer. FITC Annexin V (5 µl) and PI (5 µl) were then added and were incubated at room temperature for 15 min in the dark. Apoptotic cells were analyzed via BD FACSCalibur flow cytometer and FlowJo (V10) software (BD Biosciences).
Reactive oxygen species (ROS) assay
Intracellular ROS levels were determined using the DCFH-DA fluorescent probe (Beyotime Biotechnology). Briefly, 3×105 cells were seeded per cell in 6-well plates overnight in the cell incubator. After treatment with the indicated concentrations of neferine (0, 5, 10 and 20 µM) for 12 h, HN6, HN30 and CAL27 cells were incubated with DCFH-DA for 30 min in the cell incubator. Dichlorofluorescein (DCF) fluorescence was then detected via BD FACSCalibur flow cytometer (FITC-channel). Fluorescence microscopy (magnification, ×100; Carl Zeiss AG) was used to capture images of the cells.
Cell migration assay
The cell migration assay was performed using the Transwell system (24-wells, 8-µm pore size with polycarbonate membrane; Corning Costar; Corning, Inc.). HN30 and CAL27 cells were suspended in serum-free medium (5.0×105/ml), and 100 µl was added to the upper chamber, whereas 600 µl of complete medium (10% FBS) was added to the lower chamber. After 4 h, the media in the upper chamber was replaced with media containing various concentrations of neferine (0, 5, 10 and 20 µM, serum-free). After 36 h, the chambers were fixed with 4% paraformaldehyde for 15 min and stained with 0.1% crystal violet for 30 min at room temperature. The non-migrated cells were wiped from the upper surface of the chamber using cotton swabs. The successfully migrated cells were counted in three random fields using a light microscope (magnification, ×40; Olympus Corporation).
Scratch assay
Scratch assays were applied to determine cell mobility. First, 1×106 HN6, HN30 and CAL27 cells were seeded per well in a 6-well plate in complete medium overnight in the cell incubator to obtain a fully confluent monolayer. After 12 h of starvation with DMEM (serum-free), a 20-µl pipette tip was used to make a straight cell-free 'scratch' in each well. The cells were washed with PBS, and serum-free medium was added with various concentrations of neferine (0, 5, 10, 15 and 20 µM). Finally, the migration of the cells was captured using a phase contrast microscope (magnification, ×100; Olympus Corporation). Images of cells were obtained at the matching reference points initially and then at 12-h intervals. The wound closure of the scratch was analyzed quantitatively.
Western blot analysis
Briefly, HN6, HN30 and CAL27 cells were collected after specific treatments and lysed with RIPA buffer (Beyotime Biotechnology). The protein concentration was measured using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Inc.). A total of 20 µg protein in each sample was run on 10% SDS-PAGE gels and then electro-transferred onto a PVDF membrane (EMD Millipore). The membrane was blocked with 5% skimmed milk for 1 h at room temperature and incubated overnight with primary antibodies (1:1,000) at 4°C. The membrane was washed and incubated with HRP-conjugated secondary antibodies [cat. nos. 70-GAR0072 and 70-GAM0072; 1:5,000; Multi Sciences (LIANKE) Biotech, Co., Ltd.] for 1 h at the room temperature. Protein bands were then detected using a chemiluminescence system (Immobilion Western Chemiluminescent HRP Substrate; EMD Millipore). All bands were quantified using ImageJ V1.8. β-Actin was used as an internal control. The primary antibodies were as follows: Anti-cleaved caspase-3 (product no. 9664; Cell Signaling Technology, Inc.; and cat. no. sc-7272; Santa Cruz Biotechnology, Inc.), anti-cleaved caspase-9 (cat. no. 10380-1-AP), anti-cleaved PARP1 (cat. no. 13371-1-AP), anti-Beclin-1 (cat. no. 11306-1-AP) and anti-p62 (cat. no. 18420-1-AP) (all from ProteinTech Group, Inc.), anti-BAX (cat. no. AF0054) and anti-β-Actin (cat. no. AF0003) (both from Beyotime Biotechnology); anti-Bcl-2 (cat. no. sc-7382; Santa Cruz Biotechnology, Inc.), and anti-LC3-I/II (product code 128025; Abcam Inc.).
Transmission electron microscopy (TEM) assay
After neferine treatment (0 and 20 µM) for 24 h in the cell incubator, HN30 and CAL27 cells were fixed with 2.5% glutaraldehyde for 4 h and 1% OsO4 (Solarbio Life Science) for 1 h at 4°C, dehydrated with graded ethanol, embedded in propylene oxide, sectioned at 70 nm and stained with 2% uranyl acetate (Sigma-Aldrich; Merck KGaA) for 20 min at room temperature. The autophagosomes were visualized using electron microscopy, as previously described (22,23).
Fluorescence imaging
HN30 and CAL27 cells were seeded in 6-well plates overnight in the cell incubator and then transfected with GFP-RFP-LC3 adenovirus (108 pfu/ml MOI=10; Beyotime Biotechnology). After 24 h in the cell incubator, the medium was removed and replaced with the indicated treatments [neferine 10 µM, 24 h; EBSS (cat. no. E2888; Sigma Aldrich; Merck KGaA), 6 h; chloroquine (MCE) 10 µM, 24 h]. Autophagic flux was measured via fluorescence microscopy (magnification ×400; Carl Zeiss AG).
RNA interference
The sequence for the small interfering (si)RNA against p62 was 5′-GCA TTG AAG TTG ATA TCG AT-3′ (24). The non-targeting siRNA control was obtained from Dharmacon, Inc. CAL27 cells (3×105) were seeded per well in a 6-well plate and transfected with siRNA (75 pmol) using Lipofectamine 3000 (Invitrogen; Thermo Fisher Scientific, Inc.) for 12 h in the cell incubator. After 72 h, the transfected cells were used for the neferine experiments.
Xenograft mouse model
The animal experiments were approved by the Ethics Review Board at the Shanghai Ninth People's Hospital (Shanghai, China). CAL27 cells (2×106) suspended in 20% Matrigel (BD Biosciences) were subcutaneously injected into the dorsa of five-week-old male BALB/c nude mice (Vital River, Inc.; Charles River Laboratories, Inc.) in routine living and feeding conditions (temperature 24±2°C, humidity 40-60%, 12-h light/dark cycle, sterile feed and filtered water ad libitum). After 1 week, ten mice (tumors had formed) were randomly divided into two groups (5 mice per group). The mice were administered neferine (10 mg/kg) or PBS (control) intraperitoneally. The tumor volume was measured every 4 days (V=LengthxWidth2×0.5). The humane endpoints were as follows: i) maximum tumor volume 1,000 mm3; ii) tumor ulceration or necrosis. The mice were anesthetized with diethyl ether, then euthanized by cervical dislocation. A combination of criteria in confirming death included lack of pulse, breathing, corneal reflex, and response to firm toe pinch.
Immunohistochemical staining
Tissues were fixed with 4% paraformaldehyde for 24 h at 4°C and dehydrated and embedded in paraffin. The paraffin sections (4 µm) were deparaffinized, rehydrated and subjected to antigen reparation (microwave oven, 6 min × 4 times), endogenous peroxidase inactivation (0.3% H2O2, 15 min), and nonspecific antigen blocking (FBS; Gibco; Thermo Fisher Scientific, Inc.) for 15 min, at room temperature. The slides were then incubated with primary antibodies overnight (4°C) and, subsequently, with a secondary antibody for 15 min (at room temperature). Staining was detected using a diaminobenzidine (DAB) reagent (Zhongshan Jinqiao; ZSGB-BIO, Inc.) for 1 min at room temperature. The intensity and proportion of staining were scored by two pathologists with an Olympus light microscope (magnification, ×200). The primary antibodies were as follows: Anti-cleaved caspase-3 (product no. 9664; 1:1,000; Cell Signaling Technology, Inc.); anti-cleaved PARP1 (cat. no. 13371-1-AP; 1:200), anti-Ki67 (cat. no. 10205-2-AP; 1:500), anti-LC3 (cat. no. 14600-1-AP; 1:400) and anti-p62 (cat. no. 18420-1-AP; 1:50) (all from ProteinTech Group, Inc.). The secondary antibody was as follows: HRP-conjugated [cat. no. 70-GAR0072; 1:1,000; Multi Sciences(LIANKE) Biotech, Co., Ltd.].
Statistical analysis
Statistical comparisons between two groups were performed using non-paired Student's t-test. Statistical comparisons between multiple groups were performed by Tukey's post hoc test with one-way ANOVA. SPSS version 18.0 software (SPSS, Inc.) was used for statistical analysis. For each of the three independent experiments, the data are presented as the mean ± SEM. P<0.05 was considered to indicate a statistically significant difference.
Results
Neferine inhibits the proliferation and viability of HNSCC cells through G1 arrest
Three human HNSCC cell lines (HN6, HN30, and CAL27) were used to detect the inhibitory effect of neferine on cell proliferation via CCK-8 assays. The cell viabilities of HN6, HN30, and CAL27 were significantly decreased in a concentration- and time-dependent manner following treatment with neferine (Fig. 1A). The IC50 values at 72 h were 13.13, 21.74, and 22.54 µM in HN6, HN30, and CAL27 cells, respectively. Similarly, the colony forming capacity was inhibited by neferine, in a concentration-dependent manner (Fig. 1B). Hence, the cell cycle distribution was examined via flow cytometry, which revealed that neferine induced an obvious G1 cell cycle arrest in three cell lines. In fact, the percentage of cells in the G1 phase increased from 44.86% (0 µM) to 63.78% (20 µM), whereas that in the S phase decreased from 41.42% (0 µM) to 22.14% (20 µM) in the HN6 cells. Similar results were observed in the other two cell lines (Figs. 1C and S1A). Collectively, these results indicated that neferine exerted its inhibitory effect by inducing cell cycle arrest in HNSCC cells.
Figure 1
Neferine reduces cell viability and induces apoptosis in HNSCC cells. (A) Histograms present the cell viabilities of HN6, HN30, and CAL27 cells following treatment with neferine. Line chart depicts the IC50 values at 72 h in HN6, HN30, and CAL27 cells. (B) Plate colony formation assay showing the inhibitory effect of neferine on HNSCC cells with the indicated concentrations. (C) Cell cycle distribution of the cells treated with various concentrations of neferine for 24 h, as examined via flow cytometry. (D) Flow cytometric analysis of early and late apoptosis in the HN6, HN30, and CAL37 cells treated with neferine. (E) Apoptosis-related protein expression in the HN30 and CAL37 cells treated with neferine confirmed by western blot analysis. Left panel, HN30 and CAL37 cells treated with the indicated concentrations of neferine for 48 h. Right panel, HN30 and CAL37 cells treated with neferine (20 µM) for the indicated durations of time. *P<0.05 and **P<0.01. HNSCC, head and neck squamous cell carcinoma.
To investigate the effects of neferine on HNSCC cell motility, a scratch healing assay and Transwell assay were performed. Neferine suppressed the healing and migration of HNSCC cells in a concentration-dependent manner (Fig. S1B and C). Overall, these results indicated that neferine exhibited potential anticancer properties.
Neferine induces ROS and activates the ASK1/JNK pathway to promote apoptosis in HNSCC cells
To investigate the underlying mechanisms of neferine-induced cytotoxicity in HNSCC cells, the number of apoptotic HN6, HN30, and CAL27 cells was quantified via flow cytometry using FITC Annexin V/PI staining in the presence or absence of neferine. The results revealed that neferine increased apoptosis from 7.51% (0 µM) to 11.81% (5 µM), 27.90% (10 µM), 49.10% (15 µM), and 64.70% (20 µM) in HN6 cells (Fig. 1D). Similar trends were observed in CAL27 and HN30 cells (Figs. 1D and S2A). In addition, neferine decreased the Bcl-2/BAX ratio and triggered the cleavage of caspase-8, caspase-9, caspase-3, and PARP-1 in a concentration- and time-dependent manner (Figs. 1E and S2B). Collectively, these results indicated that neferine effectively induced apoptosis in HNSCC cells.ROS are a vital inducer of apoptosis (25,26). Therefore, to explore whether the neferine-induced apoptosis was associated with ROS hypergeneration, the ROS levels were measured via flow cytometry using the oxidation-sensitive fluorescent probe DCF. The mean fluorescence intensity of DCF in the neferine-treated HN30 cells increased by 2.62-fold (10 µM) and 3.01-fold (20 µM) compared to that in the control cells (0 µM). Similar results were observed in CAL27 cells, but not in HN6 (Fig. 2A). The fluorescence microscopy images also confirmed an increase in ROS (Fig. 2B). Moreover, considering that ROS reportedly activates the ASK1/JNK signaling pathway to induce mitochondrial apoptosis via the caspase family and Beclin-1-dependent autophagy (27,28), the expression of ASK1/JNK protein in HN30 and CAL27 cells treated with neferine was also detected. It was revealed that neferine upregulated the phosphorylation of ASK1/JNK in a concentration- and time-dependent manner; however, it did not alter the overall ASK1/JNK expression (Fig. 2C). These results indicated that neferine induced ROS generation, which activated the ASK1/JNK pathway to induce apoptosis in HNSCC cells.
Figure 2
Neferine induces ROS hypergeneration and activates the ASK1/JNK pathway to promote apoptosis and autophagosome biosynthesis in HNSCC cells. (A) Flow cytometric analysis and histograms depicting ROS abundance in HNSCC cells treated with neferine for 24 h using the oxidation-sensitive fluorescent probe DCF. (B) Fluorescence images demonstrating ROS abundance following neferine treatment. (C) Western blotting of ASK1/JNK signaling pathway proteins in HNSCC cells treated with neferine in different conditions (0, 5, 10 and 20 µM; 0, 12, 24 and 48 h). *P<0.05 and **P<0.01. HNSCC, head and neck squamous cell carcinoma; ROS, reactive oxygen species; DCF, dichlorofluorescein.
Neferine promotes the generation of autophagosomes while inhibiting autophagy influx
A previous study revealed that autophagy can be stimulated by ROS (26). Considering the indistinct interaction between apoptosis and autophagy, the effect of neferine on autophagy in the HNSCC cell lines was also explored. Specifically, Beclin-1 expression was analyzed owing to its important role in the initial steps of canonical autophagy (29). The results revealed that Beclin-1 was increased in the neferine-treated HN30 and CAL27 cells in a concentration- and time-dependent manner (Figs. 3A and S3A). Moreover, LC3 and p62 represent universal markers for autophagy. Specifically, the conversion of LC3-I to LC3-II increases as autophagosomes mature, whereas p62 is degraded in the autolysosome, causing its abundance to decrease with activated autophagic flux (29). Our results revealed the increased conversion of LC3-I to the LC3-II isoform in the neferine-treated HN30 and CAL27 cells (Figs. 3A and S3A), indicating the maturation of the autophagosomes. However, the p62 protein level also increased. TEM revealed that treatment with neferine increased the number of vacuoles containing degradative cytoplasmic materials in the HN30 and CAL27 cells (Fig. 3B).
Figure 3
Neferine promotes the generation of autophagosomes while inhibiting autophagic influx in head and neck squamous cell carcinoma cells. (A) The expression of Beclin-1, p62, and LC3 as analyzed by western blotting in HN30 and CAL27 cells following treatment with neferine at the indicated concentrations and durations of time. (B) Transmission electron microscopy of the neferine-treated (20 µM) cells depicting the number of vacuoles containing cytoplasmic materials and multivesicular bodies, a characteristic feature of degradative autophagic vacuoles. (C) Western blot analysis of p62 and LC3 expression in the HN30 and CAL27 cells concomitantly treated with neferine (20 µM) and chloroquine (10 µM). (D and E) Autophagic flux examined through double-labeled fluorescent LC3 adenovirus (mCherry+GFP−-LC3 and mCherry+GFP+-LC3). Colocalization (yellow) of both GFP (green) and mCherry (red) fluorescence indicated the generation of autophagosomes (neferine 10 µM, 24 h; EBSS 6 h; chloroquine 10 µM, 24 h). *P<0.05 and **P<0.01.
To further explore the influence of neferine on autophagy, the autophagic flux was directly monitored using an autophagosome-lysosome fusion inhibitor, chloroquine (29). First, the LC3-II levels in HN30 and CAL27 cells during neferine treatment, with or without chloroquine were examined. Co-treatment increased the LC3-II levels more significantly than chloroquine alone (Figs. 3C and S3B), indicating that neferine promoted autophagosome biosynthesis. However, p62 abundance was not further increased in the presence of chloroquine, suggesting that the neferine-induced upregulation of p62 may be caused via the inhibition of autophagic degradation (Figs. 3C and S3B). To further verify these results, the autophagic flux was also examined by transfecting double-labeled fluorescent LC3 adenovirus (mCherry-GFP-LC3) (30,31) into HN30 and CAL27 cells. Colocalization (yellow) of both GFP (green) and mCherry (red) fluorescence implied the generation of autophagosomes, whereas red puncta (mCherry+ GFP−) indicated the generation of autolysosomes. The treatment of neferine (5 µM and 12 h) was not presented, because the autophagosomes (fluorescent puncta) were little or blurry. The treatment of neferine (10 µM and 24 h) was an appropriate condition, since autophagosomes were obvious for counting and to perform the statistical analysis. As revealed in Fig. 3D and E, the yellow puncta were increased without an accompanying increase in the red puncta, indicating that the autophagic flux was blocked. These results indicated that neferine induced autophagosome biosynthesis while inhibiting autophagic flux at the final degradation step in HNSCC cell lines.
Neferine-induced apoptosis is partially mediated by autophagy influx suppression in HNSCC cells
To explore the functional relationship between neferine-induced autophagy and apoptosis, HN30 and CAL27 cells were treated with neferine (20 µM) in the presence or absence of chloroquine (10 µM) and apoptosis analysis was performed. Treatment with chloroquine alone had no obvious effect on cell apoptosis or viability in both cell lines (Fig. 4A and B). However, chloroquine further amplified neferine-induced cell cytotoxicity (Fig. 4A) and moderately intensified neferine-induced apoptosis, while inducing further activation of caspase-8, caspase-3, and PARP1 (Figs. 4B and C, and S4A and B). These results indicated that the inhibition of autophagic flux by chloroquine promoted the neferine-induced apoptosis of HN30 and CAL27 cells.
Figure 4
Neferine-induced apoptosis is partially mediated via the accumulation of p62 due to neferine-induced autophagic influx inhibition in head and neck squamous cell carcinoma cells. (A) Cell viability, (B) apoptotic cell rate, and (C) western blot analysis of cleaved caspase-8, caspase-9, caspase-3, and PARP1 in HN30 and CAL27 cells treated with neferine (20 µM) in the presence or absence of chloroquine (10 µM) for 48 h. (D) Flow cytometric analysis of early and late apoptosis and (E) western blot analysis of cleaved caspase-8, caspase-9, caspase-3, PARP1, p62, and LC3 in neferine-treated HN30 and CAL37 cells with or without p62 knockdown. *P<0.05 and **P<0.01. NC, negative control; si-, small interfering.
Since neferine was revealed to directly inhibit autophagic flux, it could be concluded that the neferine-induced apoptosis was partially enhanced by neferine-induced autophagic influx inhibition. In addition, considering that the expression of cleaved caspase-9 showed no noticeable difference between the neferine group and the neferine + chloroquine group (Figs. 4C and S4B), the further pro-apoptotic effects may be executed by caspase-8, but not caspase-9.
Accumulation of p62 due to neferine-induced autophagy influx inhibition promotes apoptosis in HNSCC cells
Previous studies have revealed that p62 acts as a 'bridge' between apoptosis and autophagy (32,33). Moreover, it was observed that the neferine-induced autophagic flux inhibition caused an increase in the p62 level (Fig. 3). Hence, to investigate the role of p62 in the neferine-induced crosstalk between apoptosis and autophagy, the expression of p62 was downregulated in CAL27 cells, the CAL27 cells were treated with neferine, and subsequently the level of apoptosis was quantified. Flow cytometric analysis revealed that p62 knockdown alleviated the neferine-induced apoptosis (from 43.3 to 29.7%) in CAL27 cells (Fig. 4D). Moreover, the cleavage of specific apoptosis-related proteins, caspase-8, caspase-3, and PARP1, was decreased; however, the same effect was not observed for cleaved caspase-9 (Figs. 4E and S4C). These results confirmed that the neferine-induced accumulation of p62 activated caspase-8 to promote apoptosis in HNSCC cells.
Neferine inhibits the growth of HNSCC cells by inducing apoptosis and autophagy in vivo
Next, to examine the effects of neferine in vivo a murine xenograft model with CAL27 cells was used. The tumor volumes following treatment with neferine were significantly smaller than that of the control. The growth rate of tumors treated with neferine was also slower than that of the control (Fig. 5A and B). Furthermore, the immunohistochemical staining of xenograft tumor tissues (Fig. 5C) revealed that treatment with neferine decreased the expression of Ki67, a marker of cell proliferation. In addition, neferine increased the expression of cleaved caspase-3 and cleaved PARP1 in the nucleus, indicating that neferine induced the apoptosis of xenograft tumors. In accordance with the in vitro results, neferine also increased the level of LC3-II and p62, indicating that neferine induced autophagosome generation and inhibited autophagy influx in vivo.
Figure 5
Neferine inhibits the growth of head and neck squamous cell carcinoma by inducing apoptosis and autophagy in vivo. (A) Representative images of xenografts constructed by CAL27 cells, treated with vehicle or neferine. (B) The line chart depicts the growth rate of tumors treated with neferine compared to the control. (C) H&E staining and immunohistochemical staining of Ki67, cleaved caspase-3, cleaved PARP1, LC3, and p62 in xenograft tumor tissues treated with neferine or vehicle. **P<0.01.
Discussion
Neferine is a plant-derived reagent that induces higher toxicity in cancer cells compared to non-transformed cells (15). It has also been reported to induce ovarian and hepatoma carcinoma cell apoptosis and autophagy (16,34); however, one study reported contradictory results indicating that neferine functions as an autophagy inhibitor in ARPE-19 (35). In addition, neither the effects of neferine on HNSCC nor the reciprocal interaction between apoptosis and autophagy induced by neferine had been previously characterized. Hence, the present study aimed to elucidate the influence of neferine on autophagy and apoptosis in HNSCCNumerous studies have reported the inhibitory effects elicited by neferine on cell proliferation, growth, migration, and angiogenesis in different tumors (10,13,16). In fact, some studies have even focused on ROS production as well as apoptosis and autophagy induction (15,34). However, most of these previous studies were independent studies that did not evaluate autophagic flux specifically. Herein, a multidimensional evaluation was conducted and the pharmacological effect of neferine was revealed to be undoubtedly versatile. First, it was revealed that neferine inhibited the viability and colony formation of cancer cells while arresting HNSCC cells in the G1/S phase. Similar results were also reported in ovarian carcinoma via the downregulation of cyclin E1 (16). Neferine was also revealed to suppress the healing and migration of HNSCC cells, further highlighting its potential anticancer properties, which were verified in an in vivo murine xenograft model. Furthermore, it was determined that neferine induced apoptosis and autophagy while increasing the level of ROS production and the activation of the ASK1/JNK pathway. Indeed, ROS served as an initiator for the activation of ASK1 (oxidative stress sensor) and JNK. Specifically, with the activation of JNK, the mitochondrial apoptosis induced by Bcl-2 inhibition and the canonical autophagy induced by JNK/Beclin-1 were sequential occurrences (36,37). Hence, neferine-induced ROS likely served as an upstream effector for apoptosis and autophagy. Moreover, the results indicated that neferine-induced autophagosome biogenesis was determined by the Beclin1-dependent canonical autophagy pathway. It was also a limitation of this study that the effect of ROS on the ASK1/JNK pathway by further interfering with ROS was absent. The treatment of neferine increased the level of ROS in HN30 and Cal27 cells, but not in HN6 cells. Although these 3 cell lines belong to head and neck squamous cell carcinoma, they have different genetic backgrounds and anatomical origins. Cell line disparity was revealed when the effect of neferine was evaluated. In addition, this result revealed that the inhibiting effects of neferine on HNSCC were not only through the ROS pathway, but also other mechanisms (for example, by the autophagic flux inhibition).Autophagy serves as a crucial mechanism for the degradation of harmful cellular components to mediate metabolic adaptation and maintain energy homeostasis (38). Several studies have revealed that autophagy exhibits a paradoxical role, having either tumor-promoting or tumor-suppressive effects on carcinoma (39,40). Moreover, the inhibition of autophagy is regarded as a universal target for anticancer therapy (41). In our research, neferine functioned as a double-edged sword for autophagy in HNSCC. It was revealed that neferine induced autophagosome generation, while also inhibiting autophagic flux at the autophagosome degradation step as evidenced by the increased conversion of LC3-I to LC3-II and the accumulation of p62.p62/SQSTM1 is involved in the formation of autophagosomes and is degraded by lysosomal proteases along with autophagosomes (42). Hence, the inhibition of autophagic flux by neferine caused the accumulation of p62. p62 is a scaffold protein composed of five domains that organize signal trafficking at critical points to regulate cell death and survival (43,44). Specifically, the UBA domain of p62 interacts with ubiquitinated proteins, thus, p62 recruits and oligomerizes important signaling molecules (44). Moreover, p62 reportedly provides a signal-organizing interface to recruit poly-ubiquitinated caspase-8 and subsequently activate caspase-8 (33). The present results revealed that neferine induced the accumulation of p62, which subsequently enhanced neferine-induced apoptosis. This was also confirmed by downregulation of p62, however, the absence of experiments using a caspase-8 inhibitor is a limitation of our study. Hence, collectively, the results indicated that p62 may function as a bridge between the autophagy and apoptosis induced by neferine.When treated with reagents that induce proteasome inhibition or endoplasmic reticular stress, cells can activate apoptosis directly through caspase-8 (45). This mechanism is strengthened by the function of LC-3 and p62 (46,47). Therefore, a novel mechanism is proposed for neferine in which the accumulation of p62 by autophagic influx inhibition promotes apoptosis through the activation of caspase-8, independent of ROS, in HNSCC cells. The involvement of p62 in neferine-induced cell apoptosis through caspase-8 activation broadened our understanding of the mechanism responsible for neferine-induced cell death. Moreover, the crosstalk between autophagy and apoptosis may have required the participation of p62 as a conjunction point in neferine-induced cell death. Considering that the activation of caspase-8 was accompanied with the accumulation of p62, it is plausible that caspase-8 may interact with p62 at the autophagosome surface during neferine treatment.In conclusion, considering the present findings of increased apoptosis and interrupted autophagic flux, our study clarified the underlying pro-apoptotic mechanism of neferine in HNSCC through the inhibition of autophagic influx mediated by p62, thereby providing new insights into the crosstalk between apoptosis and autophagy while highlighting neferine as a potential agent to improve the prognosis of HNSCC patients (Fig. 6).
Figure 6
Neferine promotes head and neck squamous cell carcinoma cell apoptosis through the accumulation of p62/SQSTM1 caused by autophagic flux inhibition. (The precise mechanism about how neferine crosses the cell membrane was unknown, thus a '?' was added in the graphic abstract).
Authors: Daniel J Klionsky; Kotb Abdelmohsen; Akihisa Abe; Md Joynal Abedin; Hagai Abeliovich; Abraham Acevedo Arozena; Hiroaki Adachi; Christopher M Adams; Peter D Adams; Khosrow Adeli; Peter J Adhihetty; Sharon G Adler; Galila Agam; Rajesh Agarwal; Manish K Aghi; Maria Agnello; Patrizia Agostinis; Patricia V Aguilar; Julio Aguirre-Ghiso; Edoardo M Airoldi; Slimane Ait-Si-Ali; Takahiko Akematsu; Emmanuel T Akporiaye; Mohamed Al-Rubeai; Guillermo M Albaiceta; Chris Albanese; Diego Albani; Matthew L Albert; Jesus Aldudo; Hana Algül; Mehrdad Alirezaei; Iraide Alloza; Alexandru Almasan; Maylin Almonte-Beceril; Emad S Alnemri; Covadonga Alonso; Nihal Altan-Bonnet; Dario C Altieri; Silvia Alvarez; Lydia Alvarez-Erviti; Sandro Alves; Giuseppina Amadoro; Atsuo Amano; Consuelo Amantini; Santiago Ambrosio; Ivano Amelio; Amal O Amer; Mohamed Amessou; Angelika Amon; Zhenyi An; Frank A Anania; Stig U Andersen; Usha P Andley; Catherine K Andreadi; Nathalie Andrieu-Abadie; Alberto Anel; David K Ann; Shailendra Anoopkumar-Dukie; Manuela Antonioli; Hiroshi Aoki; Nadezda Apostolova; Saveria Aquila; Katia Aquilano; Koichi Araki; Eli Arama; Agustin Aranda; Jun Araya; Alexandre Arcaro; Esperanza Arias; Hirokazu Arimoto; Aileen R Ariosa; Jane L Armstrong; Thierry Arnould; Ivica Arsov; Katsuhiko Asanuma; Valerie Askanas; Eric Asselin; Ryuichiro Atarashi; Sally S Atherton; Julie D Atkin; Laura D Attardi; Patrick Auberger; Georg Auburger; Laure Aurelian; Riccardo Autelli; Laura Avagliano; Maria Laura Avantaggiati; Limor Avrahami; Suresh Awale; Neelam Azad; Tiziana Bachetti; Jonathan M Backer; Dong-Hun Bae; Jae-Sung Bae; Ok-Nam Bae; Soo Han Bae; Eric H Baehrecke; Seung-Hoon Baek; Stephen Baghdiguian; Agnieszka Bagniewska-Zadworna; Hua Bai; Jie Bai; Xue-Yuan Bai; Yannick Bailly; Kithiganahalli Narayanaswamy Balaji; Walter Balduini; Andrea Ballabio; Rena Balzan; Rajkumar Banerjee; Gábor Bánhegyi; Haijun Bao; Benoit Barbeau; Maria D Barrachina; Esther Barreiro; Bonnie Bartel; Alberto Bartolomé; Diane C Bassham; Maria Teresa Bassi; Robert C Bast; Alakananda Basu; Maria Teresa Batista; Henri Batoko; Maurizio Battino; Kyle Bauckman; Bradley L Baumgarner; K Ulrich Bayer; Rupert Beale; Jean-François Beaulieu; George R Beck; Christoph Becker; J David Beckham; Pierre-André Bédard; Patrick J Bednarski; Thomas J Begley; Christian Behl; Christian Behrends; Georg Mn Behrens; Kevin E Behrns; Eloy Bejarano; Amine Belaid; Francesca Belleudi; Giovanni Bénard; Guy Berchem; Daniele Bergamaschi; Matteo Bergami; Ben Berkhout; Laura Berliocchi; Amélie Bernard; Monique Bernard; Francesca Bernassola; Anne Bertolotti; Amanda S Bess; Sébastien Besteiro; Saverio Bettuzzi; Savita Bhalla; Shalmoli Bhattacharyya; Sujit K Bhutia; Caroline Biagosch; Michele Wolfe Bianchi; Martine Biard-Piechaczyk; Viktor Billes; Claudia Bincoletto; Baris Bingol; Sara W Bird; Marc Bitoun; Ivana Bjedov; Craig Blackstone; Lionel Blanc; Guillermo A Blanco; Heidi Kiil Blomhoff; Emilio Boada-Romero; Stefan Böckler; Marianne Boes; Kathleen Boesze-Battaglia; Lawrence H Boise; Alessandra Bolino; Andrea Boman; Paolo Bonaldo; Matteo Bordi; Jürgen Bosch; Luis M Botana; Joelle Botti; German Bou; Marina Bouché; Marion Bouchecareilh; Marie-Josée Boucher; Michael E Boulton; Sebastien G Bouret; Patricia Boya; Michaël Boyer-Guittaut; Peter V Bozhkov; Nathan Brady; Vania Mm Braga; Claudio Brancolini; Gerhard H Braus; José M Bravo-San Pedro; Lisa A Brennan; Emery H Bresnick; Patrick Brest; Dave Bridges; Marie-Agnès Bringer; Marisa Brini; Glauber C Brito; Bertha Brodin; Paul S Brookes; Eric J Brown; Karen Brown; Hal E Broxmeyer; Alain Bruhat; Patricia Chakur Brum; John H Brumell; Nicola Brunetti-Pierri; Robert J Bryson-Richardson; Shilpa Buch; Alastair M Buchan; Hikmet Budak; Dmitry V Bulavin; Scott J Bultman; Geert Bultynck; Vladimir Bumbasirevic; Yan Burelle; Robert E Burke; Margit Burmeister; Peter Bütikofer; Laura Caberlotto; Ken Cadwell; Monika Cahova; Dongsheng Cai; Jingjing Cai; Qian Cai; Sara Calatayud; Nadine Camougrand; Michelangelo Campanella; Grant R Campbell; Matthew Campbell; Silvia Campello; Robin Candau; Isabella Caniggia; Lavinia Cantoni; Lizhi Cao; Allan B Caplan; Michele Caraglia; Claudio Cardinali; Sandra Morais Cardoso; Jennifer S Carew; Laura A Carleton; Cathleen R Carlin; Silvia Carloni; Sven R Carlsson; Didac Carmona-Gutierrez; Leticia Am Carneiro; Oliana Carnevali; Serena Carra; Alice Carrier; Bernadette Carroll; Caty Casas; Josefina Casas; Giuliana Cassinelli; Perrine Castets; Susana Castro-Obregon; Gabriella Cavallini; Isabella Ceccherini; Francesco Cecconi; Arthur I Cederbaum; Valentín Ceña; Simone Cenci; Claudia Cerella; Davide Cervia; Silvia Cetrullo; Hassan Chaachouay; Han-Jung Chae; Andrei S Chagin; Chee-Yin Chai; Gopal Chakrabarti; Georgios Chamilos; Edmond Yw Chan; Matthew Tv Chan; Dhyan Chandra; Pallavi Chandra; Chih-Peng Chang; Raymond Chuen-Chung Chang; Ta Yuan Chang; John C Chatham; Saurabh Chatterjee; Santosh Chauhan; Yongsheng Che; Michael E Cheetham; Rajkumar Cheluvappa; Chun-Jung Chen; Gang Chen; Guang-Chao Chen; Guoqiang Chen; Hongzhuan Chen; Jeff W Chen; Jian-Kang Chen; Min Chen; Mingzhou Chen; Peiwen Chen; Qi Chen; Quan Chen; Shang-Der Chen; Si Chen; Steve S-L Chen; Wei Chen; Wei-Jung Chen; Wen Qiang Chen; Wenli Chen; Xiangmei Chen; Yau-Hung Chen; Ye-Guang Chen; Yin Chen; Yingyu Chen; Yongshun Chen; Yu-Jen Chen; Yue-Qin Chen; Yujie Chen; Zhen Chen; Zhong Chen; Alan Cheng; Christopher Hk Cheng; Hua Cheng; Heesun Cheong; Sara Cherry; Jason Chesney; Chun Hei Antonio Cheung; Eric Chevet; Hsiang Cheng Chi; Sung-Gil Chi; Fulvio Chiacchiera; Hui-Ling Chiang; Roberto Chiarelli; Mario Chiariello; Marcello Chieppa; Lih-Shen Chin; Mario Chiong; Gigi Nc Chiu; Dong-Hyung Cho; Ssang-Goo Cho; William C Cho; Yong-Yeon Cho; Young-Seok Cho; Augustine Mk Choi; Eui-Ju Choi; Eun-Kyoung Choi; Jayoung Choi; Mary E Choi; Seung-Il Choi; Tsui-Fen Chou; Salem Chouaib; Divaker Choubey; Vinay Choubey; Kuan-Chih Chow; Kamal Chowdhury; Charleen T Chu; Tsung-Hsien Chuang; Taehoon Chun; Hyewon Chung; Taijoon Chung; Yuen-Li Chung; Yong-Joon Chwae; Valentina Cianfanelli; Roberto Ciarcia; Iwona A Ciechomska; Maria Rosa Ciriolo; Mara Cirone; Sofie Claerhout; Michael J Clague; Joan Clària; Peter Gh Clarke; Robert Clarke; Emilio Clementi; Cédric Cleyrat; Miriam Cnop; Eliana M Coccia; Tiziana Cocco; Patrice Codogno; Jörn Coers; Ezra Ew Cohen; David Colecchia; Luisa Coletto; Núria S Coll; Emma Colucci-Guyon; Sergio Comincini; Maria Condello; Katherine L Cook; Graham H Coombs; Cynthia D Cooper; J Mark Cooper; Isabelle Coppens; Maria Tiziana Corasaniti; Marco Corazzari; Ramon Corbalan; Elisabeth Corcelle-Termeau; Mario D Cordero; Cristina Corral-Ramos; Olga Corti; Andrea Cossarizza; Paola Costelli; Safia Costes; Susan L Cotman; Ana Coto-Montes; Sandra Cottet; Eduardo Couve; Lori R Covey; L Ashley Cowart; Jeffery S Cox; Fraser P Coxon; Carolyn B Coyne; Mark S Cragg; Rolf J Craven; Tiziana Crepaldi; Jose L Crespo; Alfredo Criollo; Valeria Crippa; Maria Teresa Cruz; Ana Maria Cuervo; Jose M Cuezva; Taixing Cui; Pedro R Cutillas; Mark J Czaja; Maria F Czyzyk-Krzeska; Ruben K Dagda; Uta Dahmen; Chunsun Dai; Wenjie Dai; Yun Dai; Kevin N Dalby; Luisa Dalla Valle; Guillaume Dalmasso; Marcello D'Amelio; Markus Damme; Arlette Darfeuille-Michaud; Catherine Dargemont; Victor M Darley-Usmar; Srinivasan Dasarathy; Biplab Dasgupta; Srikanta Dash; Crispin R Dass; Hazel Marie Davey; Lester M Davids; David Dávila; Roger J Davis; Ted M Dawson; Valina L Dawson; Paula Daza; Jackie de Belleroche; Paul de Figueiredo; Regina Celia Bressan Queiroz de Figueiredo; José de la Fuente; Luisa De Martino; Antonella De Matteis; Guido Ry De Meyer; Angelo De Milito; Mauro De Santi; Wanderley de Souza; Vincenzo De Tata; Daniela De Zio; Jayanta Debnath; Reinhard Dechant; Jean-Paul Decuypere; Shane Deegan; Benjamin Dehay; Barbara Del Bello; Dominic P Del Re; Régis Delage-Mourroux; Lea Md Delbridge; Louise Deldicque; Elizabeth Delorme-Axford; Yizhen Deng; Joern Dengjel; Melanie Denizot; Paul Dent; Channing J Der; Vojo Deretic; Benoît Derrien; Eric Deutsch; Timothy P Devarenne; Rodney J Devenish; Sabrina Di Bartolomeo; Nicola Di Daniele; Fabio Di Domenico; Alessia Di Nardo; Simone Di Paola; Antonio Di Pietro; Livia Di Renzo; Aaron DiAntonio; Guillermo Díaz-Araya; Ines Díaz-Laviada; Maria T Diaz-Meco; Javier Diaz-Nido; Chad A Dickey; Robert C Dickson; Marc Diederich; Paul Digard; Ivan Dikic; Savithrama P Dinesh-Kumar; Chan Ding; Wen-Xing Ding; Zufeng Ding; Luciana Dini; Jörg Hw Distler; Abhinav Diwan; Mojgan Djavaheri-Mergny; Kostyantyn Dmytruk; Renwick Cj Dobson; Volker Doetsch; Karol Dokladny; Svetlana Dokudovskaya; Massimo Donadelli; X Charlie Dong; Xiaonan Dong; Zheng Dong; Terrence M Donohue; Kelly S Doran; Gabriella D'Orazi; Gerald W Dorn; Victor Dosenko; Sami Dridi; Liat Drucker; Jie Du; Li-Lin Du; Lihuan Du; André du Toit; Priyamvada Dua; Lei Duan; Pu Duann; Vikash Kumar Dubey; Michael R Duchen; Michel A Duchosal; Helene Duez; Isabelle Dugail; Verónica I Dumit; Mara C Duncan; Elaine A Dunlop; William A Dunn; Nicolas Dupont; Luc Dupuis; Raúl V Durán; Thomas M Durcan; Stéphane Duvezin-Caubet; Umamaheswar Duvvuri; Vinay Eapen; Darius Ebrahimi-Fakhari; Arnaud Echard; Leopold Eckhart; Charles L Edelstein; Aimee L Edinger; Ludwig Eichinger; Tobias Eisenberg; Avital Eisenberg-Lerner; N Tony Eissa; Wafik S El-Deiry; Victoria El-Khoury; Zvulun Elazar; Hagit Eldar-Finkelman; Chris Jh Elliott; Enzo Emanuele; Urban Emmenegger; Nikolai Engedal; Anna-Mart Engelbrecht; Simone Engelender; Jorrit M Enserink; Ralf Erdmann; Jekaterina Erenpreisa; Rajaraman Eri; Jason L Eriksen; Andreja Erman; Ricardo Escalante; Eeva-Liisa Eskelinen; Lucile Espert; Lorena Esteban-Martínez; Thomas J Evans; Mario Fabri; Gemma Fabrias; Cinzia Fabrizi; Antonio Facchiano; Nils J Færgeman; Alberto Faggioni; W Douglas Fairlie; Chunhai Fan; Daping Fan; Jie Fan; Shengyun Fang; Manolis Fanto; Alessandro Fanzani; Thomas Farkas; Mathias Faure; Francois B Favier; Howard Fearnhead; Massimo Federici; Erkang Fei; Tania C Felizardo; Hua Feng; Yibin Feng; Yuchen Feng; Thomas A Ferguson; Álvaro F Fernández; Maite G Fernandez-Barrena; Jose C Fernandez-Checa; Arsenio Fernández-López; Martin E Fernandez-Zapico; Olivier Feron; Elisabetta Ferraro; Carmen Veríssima Ferreira-Halder; Laszlo Fesus; Ralph Feuer; Fabienne C Fiesel; Eduardo C Filippi-Chiela; Giuseppe Filomeni; Gian Maria Fimia; John H Fingert; Steven Finkbeiner; Toren Finkel; Filomena Fiorito; Paul B Fisher; Marc Flajolet; Flavio Flamigni; Oliver Florey; Salvatore Florio; R Andres Floto; Marco Folini; Carlo Follo; Edward A Fon; Francesco Fornai; Franco Fortunato; Alessandro Fraldi; Rodrigo Franco; Arnaud Francois; Aurélie François; Lisa B Frankel; Iain Dc Fraser; Norbert Frey; Damien G Freyssenet; Christian Frezza; Scott L Friedman; Daniel E Frigo; Dongxu Fu; José M Fuentes; Juan Fueyo; Yoshio Fujitani; Yuuki Fujiwara; Mikihiro Fujiya; Mitsunori Fukuda; Simone Fulda; Carmela Fusco; Bozena Gabryel; Matthias Gaestel; Philippe Gailly; Malgorzata Gajewska; Sehamuddin Galadari; Gad Galili; Inmaculada Galindo; Maria F Galindo; Giovanna Galliciotti; Lorenzo Galluzzi; Luca Galluzzi; Vincent Galy; Noor Gammoh; Sam Gandy; Anand K Ganesan; Swamynathan Ganesan; Ian G Ganley; Monique Gannagé; Fen-Biao Gao; Feng Gao; Jian-Xin Gao; Lorena García Nannig; Eleonora García Véscovi; Marina Garcia-Macía; Carmen Garcia-Ruiz; Abhishek D Garg; Pramod Kumar Garg; Ricardo Gargini; Nils Christian Gassen; Damián Gatica; Evelina Gatti; Julie Gavard; Evripidis Gavathiotis; Liang Ge; Pengfei Ge; Shengfang Ge; Po-Wu Gean; Vania Gelmetti; Armando A Genazzani; Jiefei Geng; Pascal Genschik; Lisa Gerner; Jason E Gestwicki; David A Gewirtz; Saeid Ghavami; Eric Ghigo; Debabrata Ghosh; Anna Maria Giammarioli; Francesca Giampieri; Claudia Giampietri; Alexandra Giatromanolaki; Derrick J Gibbings; Lara Gibellini; Spencer B Gibson; Vanessa Ginet; Antonio Giordano; Flaviano Giorgini; Elisa Giovannetti; Stephen E Girardin; Suzana Gispert; Sandy Giuliano; Candece L Gladson; Alvaro Glavic; Martin Gleave; Nelly Godefroy; Robert M Gogal; Kuppan Gokulan; Gustavo H Goldman; Delia Goletti; Michael S Goligorsky; Aldrin V Gomes; Ligia C Gomes; Hernando Gomez; Candelaria Gomez-Manzano; Rubén Gómez-Sánchez; Dawit Ap Gonçalves; Ebru Goncu; Qingqiu Gong; Céline Gongora; Carlos B Gonzalez; Pedro Gonzalez-Alegre; Pilar Gonzalez-Cabo; Rosa Ana González-Polo; Ing Swie Goping; Carlos Gorbea; Nikolai V Gorbunov; Daphne R Goring; Adrienne M Gorman; Sharon M Gorski; Sandro Goruppi; Shino Goto-Yamada; Cecilia Gotor; Roberta A Gottlieb; Illana Gozes; Devrim Gozuacik; Yacine Graba; Martin Graef; Giovanna E Granato; Gary Dean Grant; Steven Grant; Giovanni Luca Gravina; Douglas R Green; Alexander Greenhough; Michael T Greenwood; Benedetto Grimaldi; Frédéric Gros; Charles Grose; Jean-Francois Groulx; Florian Gruber; Paolo Grumati; Tilman Grune; Jun-Lin Guan; Kun-Liang Guan; Barbara Guerra; Carlos Guillen; Kailash Gulshan; Jan Gunst; Chuanyong Guo; Lei Guo; Ming Guo; Wenjie Guo; Xu-Guang Guo; Andrea A Gust; Åsa B Gustafsson; Elaine Gutierrez; Maximiliano G Gutierrez; Ho-Shin Gwak; Albert Haas; James E Haber; Shinji Hadano; Monica Hagedorn; David R Hahn; Andrew J Halayko; Anne Hamacher-Brady; Kozo Hamada; Ahmed Hamai; Andrea Hamann; Maho Hamasaki; Isabelle Hamer; Qutayba Hamid; Ester M Hammond; Feng Han; Weidong Han; James T Handa; John A Hanover; Malene Hansen; Masaru Harada; Ljubica Harhaji-Trajkovic; J Wade Harper; Abdel Halim Harrath; Adrian L Harris; James Harris; Udo Hasler; Peter Hasselblatt; Kazuhisa Hasui; Robert G Hawley; Teresa S Hawley; Congcong He; Cynthia Y He; Fengtian He; Gu He; Rong-Rong He; Xian-Hui He; You-Wen He; Yu-Ying He; Joan K Heath; Marie-Josée Hébert; Robert A Heinzen; Gudmundur Vignir Helgason; Michael Hensel; Elizabeth P Henske; Chengtao Her; Paul K Herman; Agustín Hernández; Carlos Hernandez; Sonia Hernández-Tiedra; Claudio Hetz; P Robin Hiesinger; Katsumi Higaki; Sabine Hilfiker; Bradford G Hill; Joseph A Hill; William D Hill; Keisuke Hino; Daniel Hofius; Paul Hofman; Günter U Höglinger; Jörg Höhfeld; Marina K Holz; Yonggeun Hong; David A Hood; Jeroen Jm Hoozemans; Thorsten Hoppe; Chin Hsu; Chin-Yuan Hsu; Li-Chung Hsu; Dong Hu; Guochang Hu; Hong-Ming Hu; Hongbo Hu; Ming Chang Hu; Yu-Chen Hu; Zhuo-Wei Hu; Fang Hua; Ya Hua; Canhua Huang; Huey-Lan Huang; Kuo-How Huang; Kuo-Yang Huang; Shile Huang; Shiqian Huang; Wei-Pang Huang; Yi-Ran Huang; Yong Huang; Yunfei Huang; Tobias B Huber; Patricia Huebbe; Won-Ki Huh; Juha J Hulmi; Gang Min Hur; James H Hurley; Zvenyslava Husak; Sabah Na Hussain; Salik Hussain; Jung Jin Hwang; Seungmin Hwang; Thomas Is Hwang; Atsuhiro Ichihara; Yuzuru Imai; Carol Imbriano; Megumi Inomata; Takeshi Into; Valentina Iovane; Juan L Iovanna; Renato V Iozzo; Nancy Y Ip; Javier E Irazoqui; Pablo Iribarren; Yoshitaka Isaka; Aleksandra J Isakovic; Harry Ischiropoulos; Jeffrey S Isenberg; Mohammad Ishaq; Hiroyuki Ishida; Isao Ishii; Jane E Ishmael; Ciro Isidoro; Ken-Ichi Isobe; Erika Isono; Shohreh Issazadeh-Navikas; Koji Itahana; Eisuke Itakura; Andrei I Ivanov; Anand Krishnan V Iyer; José M Izquierdo; Yotaro Izumi; Valentina Izzo; Marja Jäättelä; Nadia Jaber; Daniel John Jackson; William T Jackson; Tony George Jacob; Thomas S Jacques; Chinnaswamy Jagannath; Ashish Jain; Nihar Ranjan Jana; Byoung Kuk Jang; Alkesh Jani; Bassam Janji; Paulo Roberto Jannig; Patric J Jansson; Steve Jean; Marina Jendrach; Ju-Hong Jeon; Niels Jessen; Eui-Bae Jeung; Kailiang Jia; Lijun Jia; Hong Jiang; Hongchi Jiang; Liwen Jiang; Teng Jiang; Xiaoyan Jiang; Xuejun Jiang; Xuejun Jiang; Ying Jiang; Yongjun Jiang; Alberto Jiménez; Cheng Jin; Hongchuan Jin; Lei Jin; Meiyan Jin; Shengkan Jin; Umesh Kumar Jinwal; Eun-Kyeong Jo; Terje Johansen; Daniel E Johnson; Gail Vw Johnson; James D Johnson; Eric Jonasch; Chris Jones; Leo Ab Joosten; Joaquin Jordan; Anna-Maria Joseph; Bertrand Joseph; Annie M Joubert; Dianwen Ju; Jingfang Ju; Hsueh-Fen Juan; Katrin Juenemann; Gábor Juhász; Hye Seung Jung; Jae U Jung; Yong-Keun Jung; Heinz Jungbluth; Matthew J Justice; Barry Jutten; Nadeem O Kaakoush; Kai Kaarniranta; Allen Kaasik; Tomohiro Kabuta; Bertrand Kaeffer; Katarina Kågedal; Alon Kahana; Shingo Kajimura; Or Kakhlon; Manjula Kalia; Dhan V Kalvakolanu; Yoshiaki Kamada; Konstantinos Kambas; Vitaliy O Kaminskyy; Harm H Kampinga; Mustapha Kandouz; Chanhee Kang; Rui Kang; Tae-Cheon Kang; Tomotake Kanki; Thirumala-Devi Kanneganti; Haruo Kanno; Anumantha G Kanthasamy; Marc Kantorow; Maria Kaparakis-Liaskos; Orsolya Kapuy; Vassiliki Karantza; Md Razaul Karim; Parimal Karmakar; Arthur Kaser; Susmita Kaushik; Thomas Kawula; A Murat Kaynar; Po-Yuan Ke; Zun-Ji Ke; John H Kehrl; Kate E Keller; Jongsook Kim Kemper; Anne K Kenworthy; Oliver Kepp; Andreas Kern; Santosh Kesari; David Kessel; Robin Ketteler; Isis do Carmo Kettelhut; Bilon Khambu; Muzamil Majid Khan; Vinoth Km Khandelwal; Sangeeta Khare; Juliann G Kiang; Amy A Kiger; Akio Kihara; Arianna L Kim; Cheol Hyeon Kim; Deok Ryong Kim; Do-Hyung Kim; Eung Kweon Kim; Hye Young Kim; Hyung-Ryong Kim; Jae-Sung Kim; Jeong Hun Kim; Jin Cheon Kim; Jin Hyoung Kim; Kwang Woon Kim; Michael D Kim; Moon-Moo Kim; Peter K Kim; Seong Who Kim; Soo-Youl Kim; Yong-Sun Kim; Yonghyun Kim; Adi Kimchi; Alec C Kimmelman; Tomonori Kimura; Jason S King; Karla Kirkegaard; Vladimir Kirkin; Lorrie A Kirshenbaum; Shuji Kishi; Yasuo Kitajima; Katsuhiko Kitamoto; Yasushi Kitaoka; Kaio Kitazato; Rudolf A Kley; Walter T Klimecki; Michael Klinkenberg; Jochen Klucken; Helene Knævelsrud; Erwin Knecht; Laura Knuppertz; Jiunn-Liang Ko; Satoru Kobayashi; Jan C Koch; Christelle Koechlin-Ramonatxo; Ulrich Koenig; Young Ho Koh; Katja Köhler; Sepp D Kohlwein; Masato Koike; Masaaki Komatsu; Eiki Kominami; Dexin Kong; Hee Jeong Kong; Eumorphia G Konstantakou; Benjamin T Kopp; Tamas Korcsmaros; Laura Korhonen; Viktor I Korolchuk; Nadya V Koshkina; Yanjun Kou; Michael I Koukourakis; Constantinos Koumenis; Attila L Kovács; Tibor Kovács; Werner J Kovacs; Daisuke Koya; Claudine Kraft; Dimitri Krainc; Helmut Kramer; Tamara Kravic-Stevovic; Wilhelm Krek; Carole Kretz-Remy; Roswitha Krick; Malathi Krishnamurthy; Janos Kriston-Vizi; Guido Kroemer; Michael C Kruer; Rejko Kruger; Nicholas T Ktistakis; Kazuyuki Kuchitsu; Christian Kuhn; Addanki Pratap Kumar; Anuj Kumar; Ashok Kumar; Deepak Kumar; Dhiraj Kumar; Rakesh Kumar; Sharad Kumar; Mondira Kundu; Hsing-Jien Kung; Atsushi Kuno; Sheng-Han Kuo; Jeff Kuret; Tino Kurz; Terry Kwok; Taeg Kyu Kwon; Yong Tae Kwon; Irene Kyrmizi; Albert R La Spada; Frank Lafont; Tim Lahm; Aparna Lakkaraju; Truong Lam; Trond Lamark; Steve Lancel; Terry H Landowski; Darius J R Lane; Jon D Lane; Cinzia Lanzi; Pierre Lapaquette; Louis R Lapierre; Jocelyn Laporte; Johanna Laukkarinen; Gordon W Laurie; Sergio Lavandero; Lena Lavie; Matthew J LaVoie; Betty Yuen Kwan Law; Helen Ka-Wai Law; Kelsey B Law; Robert Layfield; Pedro A Lazo; Laurent Le Cam; Karine G Le Roch; Hervé Le Stunff; Vijittra Leardkamolkarn; Marc Lecuit; Byung-Hoon Lee; Che-Hsin Lee; Erinna F Lee; Gyun Min Lee; He-Jin Lee; Hsinyu Lee; Jae Keun Lee; Jongdae Lee; Ju-Hyun Lee; Jun Hee Lee; Michael Lee; Myung-Shik Lee; Patty J Lee; Sam W Lee; Seung-Jae Lee; Shiow-Ju Lee; Stella Y Lee; Sug Hyung Lee; Sung Sik Lee; Sung-Joon Lee; Sunhee Lee; Ying-Ray Lee; Yong J Lee; Young H Lee; Christiaan Leeuwenburgh; Sylvain Lefort; Renaud Legouis; Jinzhi Lei; Qun-Ying Lei; David A Leib; Gil Leibowitz; Istvan Lekli; Stéphane D Lemaire; John J Lemasters; Marius K Lemberg; Antoinette Lemoine; Shuilong Leng; Guido Lenz; Paola Lenzi; Lilach O Lerman; Daniele Lettieri Barbato; Julia I-Ju Leu; Hing Y Leung; Beth Levine; Patrick A Lewis; Frank Lezoualc'h; Chi Li; Faqiang Li; Feng-Jun Li; Jun Li; Ke Li; Lian Li; Min Li; Min Li; Qiang Li; Rui Li; Sheng Li; Wei Li; Wei Li; Xiaotao Li; Yumin Li; Jiqin Lian; Chengyu Liang; Qiangrong Liang; Yulin Liao; Joana Liberal; Pawel P Liberski; Pearl Lie; Andrew P Lieberman; Hyunjung Jade Lim; Kah-Leong Lim; Kyu Lim; Raquel T Lima; Chang-Shen Lin; Chiou-Feng Lin; Fang Lin; Fangming Lin; Fu-Cheng Lin; Kui Lin; Kwang-Huei Lin; Pei-Hui Lin; Tianwei Lin; Wan-Wan Lin; Yee-Shin Lin; Yong Lin; Rafael Linden; Dan Lindholm; Lisa M Lindqvist; Paul Lingor; Andreas Linkermann; Lance A Liotta; Marta M Lipinski; Vitor A Lira; Michael P Lisanti; Paloma B Liton; Bo Liu; Chong Liu; Chun-Feng Liu; Fei Liu; Hung-Jen Liu; Jianxun Liu; Jing-Jing Liu; Jing-Lan Liu; Ke Liu; Leyuan Liu; Liang Liu; Quentin Liu; Rong-Yu Liu; Shiming Liu; Shuwen Liu; Wei Liu; Xian-De Liu; Xiangguo Liu; Xiao-Hong Liu; Xinfeng Liu; Xu Liu; Xueqin Liu; Yang Liu; Yule Liu; Zexian Liu; Zhe Liu; Juan P Liuzzi; Gérard Lizard; Mila Ljujic; Irfan J Lodhi; Susan E Logue; Bal L Lokeshwar; Yun Chau Long; Sagar Lonial; Benjamin Loos; Carlos López-Otín; Cristina López-Vicario; Mar Lorente; Philip L Lorenzi; Péter Lõrincz; Marek Los; Michael T Lotze; Penny E Lovat; Binfeng Lu; Bo Lu; Jiahong Lu; Qing Lu; She-Min Lu; Shuyan Lu; Yingying Lu; Frédéric Luciano; Shirley Luckhart; John Milton Lucocq; Paula Ludovico; Aurelia Lugea; Nicholas W Lukacs; Julian J Lum; Anders H Lund; Honglin Luo; Jia Luo; Shouqing Luo; Claudio Luparello; Timothy Lyons; Jianjie Ma; Yi Ma; Yong Ma; Zhenyi Ma; Juliano Machado; Glaucia M Machado-Santelli; Fernando Macian; Gustavo C MacIntosh; Jeffrey P MacKeigan; Kay F Macleod; John D MacMicking; Lee Ann MacMillan-Crow; Frank Madeo; Muniswamy Madesh; Julio Madrigal-Matute; Akiko Maeda; Tatsuya Maeda; Gustavo Maegawa; Emilia Maellaro; Hannelore Maes; Marta Magariños; Kenneth Maiese; Tapas K Maiti; Luigi Maiuri; Maria Chiara Maiuri; Carl G Maki; Roland Malli; Walter Malorni; Alina Maloyan; Fathia Mami-Chouaib; Na Man; Joseph D Mancias; Eva-Maria Mandelkow; Michael A Mandell; Angelo A Manfredi; Serge N Manié; Claudia Manzoni; Kai Mao; Zixu Mao; Zong-Wan Mao; Philippe Marambaud; Anna Maria Marconi; Zvonimir Marelja; Gabriella Marfe; Marta Margeta; Eva Margittai; Muriel Mari; Francesca V Mariani; Concepcio Marin; Sara Marinelli; Guillermo Mariño; Ivanka Markovic; Rebecca Marquez; Alberto M Martelli; Sascha Martens; Katie R Martin; Seamus J Martin; Shaun Martin; Miguel A Martin-Acebes; Paloma Martín-Sanz; Camille Martinand-Mari; Wim Martinet; Jennifer Martinez; Nuria Martinez-Lopez; Ubaldo Martinez-Outschoorn; Moisés Martínez-Velázquez; Marta Martinez-Vicente; Waleska Kerllen Martins; Hirosato Mashima; James A Mastrianni; Giuseppe Matarese; Paola Matarrese; Roberto Mateo; Satoaki Matoba; Naomichi Matsumoto; Takehiko Matsushita; Akira Matsuura; Takeshi Matsuzawa; Mark P Mattson; Soledad Matus; Norma Maugeri; Caroline Mauvezin; Andreas Mayer; Dusica Maysinger; Guillermo D Mazzolini; Mary Kate McBrayer; Kimberly McCall; Craig McCormick; Gerald M McInerney; Skye C McIver; Sharon McKenna; John J McMahon; Iain A McNeish; Fatima Mechta-Grigoriou; Jan Paul Medema; Diego L Medina; Klara Megyeri; Maryam Mehrpour; Jawahar L Mehta; Yide Mei; Ute-Christiane Meier; Alfred J Meijer; Alicia Meléndez; Gerry Melino; Sonia Melino; Edesio Jose Tenorio de Melo; Maria A Mena; Marc D Meneghini; Javier A Menendez; Regina Menezes; Liesu Meng; Ling-Hua Meng; Songshu Meng; Rossella Menghini; A Sue Menko; Rubem Fs Menna-Barreto; Manoj B Menon; Marco A Meraz-Ríos; Giuseppe Merla; Luciano Merlini; Angelica M Merlot; Andreas Meryk; Stefania Meschini; Joel N Meyer; Man-Tian Mi; Chao-Yu Miao; Lucia Micale; Simon Michaeli; Carine Michiels; Anna Rita Migliaccio; Anastasia Susie Mihailidou; Dalibor Mijaljica; Katsuhiko Mikoshiba; Enrico Milan; Leonor Miller-Fleming; Gordon B Mills; Ian G Mills; Georgia Minakaki; Berge A Minassian; Xiu-Fen Ming; Farida Minibayeva; Elena A Minina; Justine D Mintern; Saverio Minucci; Antonio Miranda-Vizuete; Claire H Mitchell; Shigeki Miyamoto; Keisuke Miyazawa; Noboru Mizushima; Katarzyna Mnich; Baharia Mograbi; Simin Mohseni; Luis Ferreira Moita; Marco Molinari; Maurizio Molinari; Andreas Buch Møller; Bertrand Mollereau; Faustino Mollinedo; Marco Mongillo; Martha M Monick; Serena Montagnaro; Craig Montell; Darren J Moore; Michael N Moore; Rodrigo Mora-Rodriguez; Paula I Moreira; Etienne Morel; Maria Beatrice Morelli; Sandra Moreno; Michael J Morgan; Arnaud Moris; Yuji Moriyasu; Janna L Morrison; Lynda A Morrison; Eugenia Morselli; Jorge Moscat; Pope L Moseley; Serge Mostowy; Elisa Motori; Denis Mottet; Jeremy C Mottram; Charbel E-H Moussa; Vassiliki E Mpakou; Hasan Mukhtar; Jean M Mulcahy Levy; Sylviane Muller; Raquel Muñoz-Moreno; Cristina Muñoz-Pinedo; Christian Münz; Maureen E Murphy; James T Murray; Aditya Murthy; Indira U Mysorekar; Ivan R Nabi; Massimo Nabissi; Gustavo A Nader; Yukitoshi Nagahara; Yoshitaka Nagai; Kazuhiro Nagata; Anika Nagelkerke; Péter Nagy; Samisubbu R Naidu; Sreejayan Nair; Hiroyasu Nakano; Hitoshi Nakatogawa; Meera Nanjundan; Gennaro Napolitano; Naweed I Naqvi; Roberta Nardacci; Derek P Narendra; Masashi Narita; Anna Chiara Nascimbeni; Ramesh Natarajan; Luiz C Navegantes; Steffan T Nawrocki; Taras Y Nazarko; Volodymyr Y Nazarko; Thomas Neill; Luca M Neri; Mihai G Netea; Romana T Netea-Maier; Bruno M Neves; Paul A Ney; Ioannis P Nezis; Hang Tt Nguyen; Huu Phuc Nguyen; Anne-Sophie Nicot; Hilde Nilsen; Per Nilsson; Mikio Nishimura; Ichizo Nishino; Mireia Niso-Santano; Hua Niu; Ralph A Nixon; Vincent Co Njar; Takeshi Noda; Angelika A Noegel; Elsie Magdalena Nolte; Erik Norberg; Koenraad K Norga; Sakineh Kazemi Noureini; Shoji Notomi; Lucia Notterpek; Karin Nowikovsky; Nobuyuki Nukina; Thorsten Nürnberger; Valerie B O'Donnell; Tracey O'Donovan; Peter J O'Dwyer; Ina Oehme; Clara L Oeste; Michinaga Ogawa; Besim Ogretmen; Yuji Ogura; Young J Oh; Masaki Ohmuraya; Takayuki Ohshima; Rani Ojha; Koji Okamoto; Toshiro Okazaki; F Javier Oliver; Karin Ollinger; Stefan Olsson; Daniel P Orban; Paulina Ordonez; Idil Orhon; Laszlo Orosz; Eyleen J O'Rourke; Helena Orozco; Angel L Ortega; Elena Ortona; Laura D Osellame; Junko Oshima; Shigeru Oshima; Heinz D Osiewacz; Takanobu Otomo; Kinya Otsu; Jing-Hsiung James Ou; Tiago F Outeiro; Dong-Yun Ouyang; Hongjiao Ouyang; Michael Overholtzer; Michelle A Ozbun; P Hande Ozdinler; Bulent Ozpolat; Consiglia Pacelli; Paolo Paganetti; Guylène Page; Gilles Pages; Ugo Pagnini; Beata Pajak; Stephen C Pak; Karolina Pakos-Zebrucka; Nazzy Pakpour; Zdena Palková; Francesca Palladino; Kathrin Pallauf; Nicolas Pallet; Marta Palmieri; Søren R Paludan; Camilla Palumbo; Silvia Palumbo; Olatz Pampliega; Hongming Pan; Wei Pan; Theocharis Panaretakis; Aseem Pandey; Areti Pantazopoulou; Zuzana Papackova; Daniela L Papademetrio; Issidora Papassideri; Alessio Papini; Nirmala Parajuli; Julian Pardo; Vrajesh V Parekh; Giancarlo Parenti; Jong-In Park; Junsoo Park; Ohkmae K Park; Roy Parker; Rosanna Parlato; Jan B Parys; Katherine R Parzych; Jean-Max Pasquet; Benoit Pasquier; Kishore Bs Pasumarthi; Daniel Patschan; Cam Patterson; Sophie Pattingre; Scott Pattison; Arnim Pause; Hermann Pavenstädt; Flaminia Pavone; Zully Pedrozo; Fernando J Peña; Miguel A Peñalva; Mario Pende; Jianxin Peng; Fabio Penna; Josef M Penninger; Anna Pensalfini; Salvatore Pepe; Gustavo Js Pereira; Paulo C Pereira; Verónica Pérez-de la Cruz; María Esther Pérez-Pérez; Diego Pérez-Rodríguez; Dolores Pérez-Sala; Celine Perier; Andras Perl; David H Perlmutter; Ida Perrotta; Shazib Pervaiz; Maija Pesonen; Jeffrey E Pessin; Godefridus J Peters; Morten Petersen; Irina Petrache; Basil J Petrof; Goran Petrovski; James M Phang; Mauro Piacentini; Marina Pierdominici; Philippe Pierre; Valérie Pierrefite-Carle; Federico Pietrocola; Felipe X Pimentel-Muiños; Mario Pinar; Benjamin Pineda; Ronit Pinkas-Kramarski; Marcello Pinti; Paolo Pinton; Bilal Piperdi; James M Piret; Leonidas C Platanias; Harald W Platta; Edward D Plowey; Stefanie Pöggeler; Marc Poirot; Peter Polčic; Angelo Poletti; Audrey H Poon; Hana Popelka; Blagovesta Popova; Izabela Poprawa; Shibu M Poulose; Joanna Poulton; Scott K Powers; Ted Powers; Mercedes Pozuelo-Rubio; Krisna Prak; Reinhild Prange; Mark Prescott; Muriel Priault; Sharon Prince; Richard L Proia; Tassula Proikas-Cezanne; Holger Prokisch; Vasilis J Promponas; Karin Przyklenk; Rosa Puertollano; Subbiah Pugazhenthi; Luigi Puglielli; Aurora Pujol; Julien Puyal; Dohun Pyeon; Xin Qi; Wen-Bin Qian; Zheng-Hong Qin; Yu Qiu; Ziwei Qu; Joe Quadrilatero; Frederick Quinn; Nina Raben; Hannah Rabinowich; Flavia Radogna; Michael J Ragusa; Mohamed Rahmani; Komal Raina; Sasanka Ramanadham; Rajagopal Ramesh; Abdelhaq Rami; Sarron Randall-Demllo; Felix Randow; Hai Rao; V Ashutosh Rao; Blake B Rasmussen; Tobias M Rasse; Edward A Ratovitski; Pierre-Emmanuel Rautou; Swapan K Ray; Babak Razani; Bruce H Reed; Fulvio Reggiori; Markus Rehm; Andreas S Reichert; Theo Rein; David J Reiner; Eric Reits; Jun Ren; Xingcong Ren; Maurizio Renna; Jane Eb Reusch; Jose L Revuelta; Leticia Reyes; Alireza R Rezaie; Robert I Richards; Des R Richardson; Clémence Richetta; Michael A Riehle; Bertrand H Rihn; Yasuko Rikihisa; Brigit E Riley; Gerald Rimbach; Maria Rita Rippo; Konstantinos Ritis; Federica Rizzi; Elizete Rizzo; Peter J Roach; Jeffrey Robbins; Michel Roberge; Gabriela Roca; Maria Carmela Roccheri; Sonia Rocha; Cecilia Mp Rodrigues; Clara I Rodríguez; Santiago Rodriguez de Cordoba; Natalia Rodriguez-Muela; Jeroen Roelofs; Vladimir V Rogov; Troy T Rohn; Bärbel Rohrer; Davide Romanelli; Luigina Romani; Patricia Silvia Romano; M Isabel G Roncero; Jose Luis Rosa; Alicia Rosello; Kirill V Rosen; Philip Rosenstiel; Magdalena Rost-Roszkowska; Kevin A Roth; Gael Roué; Mustapha Rouis; Kasper M Rouschop; Daniel T Ruan; Diego Ruano; David C Rubinsztein; Edmund B Rucker; Assaf Rudich; Emil Rudolf; Ruediger Rudolf; Markus A Ruegg; Carmen Ruiz-Roldan; Avnika Ashok Ruparelia; Paola Rusmini; David W Russ; Gian Luigi Russo; Giuseppe Russo; Rossella Russo; Tor Erik Rusten; Victoria Ryabovol; Kevin M Ryan; Stefan W Ryter; David M Sabatini; Michael Sacher; Carsten Sachse; Michael N Sack; Junichi Sadoshima; Paul Saftig; Ronit Sagi-Eisenberg; Sumit Sahni; Pothana Saikumar; Tsunenori Saito; Tatsuya Saitoh; Koichi Sakakura; Machiko Sakoh-Nakatogawa; Yasuhito Sakuraba; María Salazar-Roa; Paolo Salomoni; Ashok K Saluja; Paul M Salvaterra; Rosa Salvioli; Afshin Samali; Anthony Mj Sanchez; José A Sánchez-Alcázar; Ricardo Sanchez-Prieto; Marco Sandri; Miguel A Sanjuan; Stefano Santaguida; Laura Santambrogio; Giorgio Santoni; Claudia Nunes Dos Santos; Shweta Saran; Marco Sardiello; Graeme Sargent; Pallabi Sarkar; Sovan Sarkar; Maria Rosa Sarrias; Minnie M Sarwal; Chihiro Sasakawa; Motoko Sasaki; Miklos Sass; Ken Sato; Miyuki Sato; Joseph Satriano; Niramol Savaraj; Svetlana Saveljeva; Liliana Schaefer; Ulrich E Schaible; Michael Scharl; Hermann M Schatzl; Randy Schekman; Wiep Scheper; Alfonso Schiavi; Hyman M Schipper; Hana Schmeisser; Jens Schmidt; Ingo Schmitz; Bianca E Schneider; E Marion Schneider; Jaime L Schneider; Eric A Schon; Miriam J Schönenberger; Axel H Schönthal; Daniel F Schorderet; Bernd Schröder; Sebastian Schuck; Ryan J Schulze; Melanie Schwarten; Thomas L Schwarz; Sebastiano Sciarretta; Kathleen Scotto; A Ivana Scovassi; Robert A Screaton; Mark Screen; Hugo Seca; Simon Sedej; Laura Segatori; Nava Segev; Per O Seglen; Jose M Seguí-Simarro; Juan Segura-Aguilar; Ekihiro Seki; Christian Sell; Iban Seiliez; Clay F Semenkovich; Gregg L Semenza; Utpal Sen; Andreas L Serra; Ana Serrano-Puebla; Hiromi Sesaki; Takao Setoguchi; Carmine Settembre; John J Shacka; Ayesha N Shajahan-Haq; Irving M Shapiro; Shweta Sharma; Hua She; C-K James Shen; Chiung-Chyi Shen; Han-Ming Shen; Sanbing Shen; Weili Shen; Rui Sheng; Xianyong Sheng; Zu-Hang Sheng; Trevor G Shepherd; Junyan Shi; Qiang Shi; Qinghua Shi; Yuguang Shi; Shusaku Shibutani; Kenichi Shibuya; Yoshihiro Shidoji; Jeng-Jer Shieh; Chwen-Ming Shih; Yohta Shimada; Shigeomi Shimizu; Dong Wook Shin; Mari L Shinohara; Michiko Shintani; Takahiro Shintani; Tetsuo Shioi; Ken Shirabe; Ronit Shiri-Sverdlov; Orian Shirihai; Gordon C Shore; Chih-Wen Shu; Deepak Shukla; Andriy A Sibirny; Valentina Sica; Christina J Sigurdson; Einar M Sigurdsson; Puran Singh Sijwali; Beata Sikorska; Wilian A Silveira; Sandrine Silvente-Poirot; Gary A Silverman; Jan Simak; Thomas Simmet; Anna Katharina Simon; Hans-Uwe Simon; Cristiano Simone; Matias Simons; Anne Simonsen; Rajat Singh; Shivendra V Singh; Shrawan K Singh; Debasish Sinha; Sangita Sinha; Frank A Sinicrope; Agnieszka Sirko; Kapil Sirohi; Balindiwe Jn Sishi; Annie Sittler; Parco M Siu; Efthimios Sivridis; Anna Skwarska; Ruth Slack; Iva Slaninová; Nikolai Slavov; Soraya S Smaili; Keiran Sm Smalley; Duncan R Smith; Stefaan J Soenen; Scott A Soleimanpour; Anita Solhaug; Kumaravel Somasundaram; Jin H Son; Avinash Sonawane; Chunjuan Song; Fuyong Song; Hyun Kyu Song; Ju-Xian Song; Wei Song; Kai Y Soo; Anil K Sood; Tuck Wah Soong; Virawudh Soontornniyomkij; Maurizio Sorice; Federica Sotgia; David R Soto-Pantoja; Areechun Sotthibundhu; Maria João Sousa; Herman P Spaink; Paul N Span; Anne Spang; Janet D Sparks; Peter G Speck; Stephen A Spector; Claudia D Spies; Wolfdieter Springer; Daret St Clair; Alessandra Stacchiotti; Bart Staels; Michael T Stang; Daniel T Starczynowski; Petro Starokadomskyy; Clemens Steegborn; John W Steele; Leonidas Stefanis; Joan Steffan; Christine M Stellrecht; Harald Stenmark; Tomasz M Stepkowski; Stęphan T Stern; Craig Stevens; Brent R Stockwell; Veronika Stoka; Zuzana Storchova; Björn Stork; Vassilis Stratoulias; Dimitrios J Stravopodis; Pavel Strnad; Anne Marie Strohecker; Anna-Lena Ström; Per Stromhaug; Jiri Stulik; Yu-Xiong Su; Zhaoliang Su; Carlos S Subauste; Srinivasa Subramaniam; Carolyn M Sue; Sang Won Suh; Xinbing Sui; Supawadee Sukseree; David Sulzer; Fang-Lin Sun; Jiaren Sun; Jun Sun; Shi-Yong Sun; Yang Sun; Yi Sun; Yingjie Sun; Vinod Sundaramoorthy; Joseph Sung; Hidekazu Suzuki; Kuninori Suzuki; Naoki Suzuki; Tadashi Suzuki; Yuichiro J Suzuki; Michele S Swanson; Charles Swanton; Karl Swärd; Ghanshyam Swarup; Sean T Sweeney; Paul W Sylvester; Zsuzsanna Szatmari; Eva Szegezdi; Peter W Szlosarek; Heinrich Taegtmeyer; Marco Tafani; Emmanuel Taillebourg; Stephen Wg Tait; Krisztina Takacs-Vellai; Yoshinori Takahashi; Szabolcs Takáts; Genzou Takemura; Nagio Takigawa; Nicholas J Talbot; Elena Tamagno; Jerome Tamburini; Cai-Ping Tan; Lan Tan; Mei Lan Tan; Ming Tan; Yee-Joo Tan; Keiji Tanaka; Masaki Tanaka; Daolin Tang; Dingzhong Tang; Guomei Tang; Isei Tanida; Kunikazu Tanji; Bakhos A Tannous; Jose A Tapia; Inmaculada Tasset-Cuevas; Marc Tatar; Iman Tavassoly; Nektarios Tavernarakis; Allen Taylor; Graham S Taylor; Gregory A Taylor; J Paul Taylor; Mark J Taylor; Elena V Tchetina; Andrew R Tee; Fatima Teixeira-Clerc; Sucheta Telang; Tewin Tencomnao; Ba-Bie Teng; Ru-Jeng Teng; Faraj Terro; Gianluca Tettamanti; Arianne L Theiss; Anne E Theron; Kelly Jean Thomas; Marcos P Thomé; Paul G Thomes; Andrew Thorburn; Jeremy Thorner; Thomas Thum; Michael Thumm; Teresa Lm Thurston; Ling Tian; Andreas Till; Jenny Pan-Yun Ting; Vladimir I Titorenko; Lilach Toker; Stefano Toldo; Sharon A Tooze; Ivan Topisirovic; Maria Lyngaas Torgersen; Liliana Torosantucci; Alicia Torriglia; Maria Rosaria Torrisi; Cathy Tournier; Roberto Towns; Vladimir Trajkovic; Leonardo H Travassos; Gemma Triola; Durga Nand Tripathi; Daniela Trisciuoglio; Rodrigo Troncoso; Ioannis P Trougakos; Anita C Truttmann; Kuen-Jer Tsai; Mario P Tschan; Yi-Hsin Tseng; Takayuki Tsukuba; Allan Tsung; Andrey S Tsvetkov; Shuiping Tu; Hsing-Yu Tuan; Marco Tucci; David A Tumbarello; Boris Turk; Vito Turk; Robin Fb Turner; Anders A Tveita; Suresh C Tyagi; Makoto Ubukata; Yasuo Uchiyama; Andrej Udelnow; Takashi Ueno; Midori Umekawa; Rika Umemiya-Shirafuji; Benjamin R Underwood; Christian Ungermann; Rodrigo P Ureshino; Ryo Ushioda; Vladimir N Uversky; Néstor L Uzcátegui; Thomas Vaccari; Maria I Vaccaro; Libuše Váchová; Helin Vakifahmetoglu-Norberg; Rut Valdor; Enza Maria Valente; Francois Vallette; Angela M Valverde; Greet Van den Berghe; Ludo Van Den Bosch; Gijs R van den Brink; F Gisou van der Goot; Ida J van der Klei; Luc Jw van der Laan; Wouter G van Doorn; Marjolein van Egmond; Kenneth L van Golen; Luc Van Kaer; Menno van Lookeren Campagne; Peter Vandenabeele; Wim Vandenberghe; Ilse Vanhorebeek; Isabel Varela-Nieto; M Helena Vasconcelos; Radovan Vasko; Demetrios G Vavvas; Ignacio Vega-Naredo; Guillermo Velasco; Athanassios D Velentzas; Panagiotis D Velentzas; Tibor Vellai; Edo Vellenga; Mikkel Holm Vendelbo; Kartik Venkatachalam; Natascia Ventura; Salvador Ventura; Patrícia St Veras; Mireille Verdier; Beata G Vertessy; Andrea Viale; Michel Vidal; Helena L A Vieira; Richard D Vierstra; Nadarajah Vigneswaran; Neeraj Vij; Miquel Vila; Margarita Villar; Victor H Villar; Joan Villarroya; Cécile Vindis; Giampietro Viola; Maria Teresa Viscomi; Giovanni Vitale; Dan T Vogl; Olga V Voitsekhovskaja; Clarissa von Haefen; Karin von Schwarzenberg; Daniel E Voth; Valérie Vouret-Craviari; Kristina Vuori; Jatin M Vyas; Christian Waeber; Cheryl Lyn Walker; Mark J Walker; Jochen Walter; Lei Wan; Xiangbo Wan; Bo Wang; Caihong Wang; Chao-Yung Wang; Chengshu Wang; Chenran Wang; Chuangui Wang; Dong Wang; Fen Wang; Fuxin Wang; Guanghui Wang; Hai-Jie Wang; Haichao Wang; Hong-Gang Wang; Hongmin Wang; Horng-Dar Wang; Jing Wang; Junjun Wang; Mei Wang; Mei-Qing Wang; Pei-Yu Wang; Peng Wang; Richard C Wang; Shuo Wang; Ting-Fang Wang; Xian Wang; Xiao-Jia Wang; Xiao-Wei Wang; Xin Wang; Xuejun Wang; Yan Wang; Yanming Wang; Ying Wang; Ying-Jan Wang; Yipeng Wang; Yu Wang; Yu Tian Wang; Yuqing Wang; Zhi-Nong Wang; Pablo Wappner; Carl Ward; Diane McVey Ward; Gary Warnes; Hirotaka Watada; Yoshihisa Watanabe; Kei Watase; Timothy E Weaver; Colin D Weekes; Jiwu Wei; Thomas Weide; Conrad C Weihl; Günther Weindl; Simone Nardin Weis; Longping Wen; Xin Wen; Yunfei Wen; Benedikt Westermann; Cornelia M Weyand; Anthony R White; Eileen White; J Lindsay Whitton; Alexander J Whitworth; Joëlle Wiels; Franziska Wild; Manon E Wildenberg; Tom Wileman; Deepti Srinivas Wilkinson; Simon Wilkinson; Dieter Willbold; Chris Williams; Katherine Williams; Peter R Williamson; Konstanze F Winklhofer; Steven S Witkin; Stephanie E Wohlgemuth; Thomas Wollert; Ernst J Wolvetang; Esther Wong; G William Wong; Richard W Wong; Vincent Kam Wai Wong; Elizabeth A Woodcock; Karen L Wright; Chunlai Wu; Defeng Wu; Gen Sheng Wu; Jian Wu; Junfang Wu; Mian Wu; Min Wu; Shengzhou Wu; William Kk Wu; Yaohua Wu; Zhenlong Wu; Cristina Pr Xavier; Ramnik J Xavier; Gui-Xian Xia; Tian Xia; Weiliang Xia; Yong Xia; Hengyi Xiao; Jian Xiao; Shi Xiao; Wuhan Xiao; Chuan-Ming Xie; Zhiping Xie; Zhonglin Xie; Maria Xilouri; Yuyan Xiong; Chuanshan Xu; Congfeng Xu; Feng Xu; Haoxing Xu; Hongwei Xu; Jian Xu; Jianzhen Xu; Jinxian Xu; Liang Xu; Xiaolei Xu; Yangqing Xu; Ye Xu; Zhi-Xiang Xu; Ziheng Xu; Yu Xue; Takahiro Yamada; Ai Yamamoto; Koji Yamanaka; Shunhei Yamashina; Shigeko Yamashiro; Bing Yan; Bo Yan; Xianghua Yan; Zhen Yan; Yasuo Yanagi; Dun-Sheng Yang; Jin-Ming Yang; Liu Yang; Minghua Yang; Pei-Ming Yang; Peixin Yang; Qian Yang; Wannian Yang; Wei Yuan Yang; Xuesong Yang; Yi Yang; Ying Yang; Zhifen Yang; Zhihong Yang; Meng-Chao Yao; Pamela J Yao; Xiaofeng Yao; Zhenyu Yao; Zhiyuan Yao; Linda S Yasui; Mingxiang Ye; Barry Yedvobnick; Behzad Yeganeh; Elizabeth S Yeh; Patricia L Yeyati; Fan Yi; Long Yi; Xiao-Ming Yin; Calvin K Yip; Yeong-Min Yoo; Young Hyun Yoo; Seung-Yong Yoon; Ken-Ichi Yoshida; Tamotsu Yoshimori; Ken H Young; Huixin Yu; Jane J Yu; Jin-Tai Yu; Jun Yu; Li Yu; W Haung Yu; Xiao-Fang Yu; Zhengping Yu; Junying Yuan; Zhi-Min Yuan; Beatrice Yjt Yue; Jianbo Yue; Zhenyu Yue; David N Zacks; Eldad Zacksenhaus; Nadia Zaffaroni; Tania Zaglia; Zahra Zakeri; Vincent Zecchini; Jinsheng Zeng; Min Zeng; Qi Zeng; Antonis S Zervos; Donna D Zhang; Fan Zhang; Guo Zhang; Guo-Chang Zhang; Hao Zhang; Hong Zhang; Hong Zhang; Hongbing Zhang; Jian Zhang; Jian Zhang; Jiangwei Zhang; Jianhua Zhang; Jing-Pu Zhang; Li Zhang; Lin Zhang; Lin Zhang; Long Zhang; Ming-Yong Zhang; Xiangnan Zhang; Xu Dong Zhang; Yan Zhang; Yang Zhang; Yanjin Zhang; Yingmei Zhang; Yunjiao Zhang; Mei Zhao; Wei-Li Zhao; Xiaonan Zhao; Yan G Zhao; Ying Zhao; Yongchao Zhao; Yu-Xia Zhao; Zhendong Zhao; Zhizhuang J Zhao; Dexian Zheng; Xi-Long Zheng; Xiaoxiang Zheng; Boris Zhivotovsky; Qing Zhong; Guang-Zhou Zhou; Guofei Zhou; Huiping Zhou; Shu-Feng Zhou; Xu-Jie Zhou; Hongxin Zhu; Hua Zhu; Wei-Guo Zhu; Wenhua Zhu; Xiao-Feng Zhu; Yuhua Zhu; Shi-Mei Zhuang; Xiaohong Zhuang; Elio Ziparo; Christos E Zois; Teresa Zoladek; Wei-Xing Zong; Antonio Zorzano; Susu M Zughaier Journal: Autophagy Date: 2016 Impact factor: 16.016
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6